Boston Scientific Corporation Q3 2025 Earnings Recap

BSX Q3 2025 October 23, 2025

Get alerts when BSX reports next quarter

Boston Scientific's Q3 2025 results surpassed expectations with 19% operational sales growth and a 15% increase in organic sales, driven by strong performances in Cardiovascular and MedSurg segments.

Earnings Per Share Beat

$0.75 vs $0.71 est.

+5.0% surprise

Revenue Beat

5065000000 vs 4968967646 est.

+1.9% surprise

Market Reaction

1-Day -1.25%

5-Day -1.78%

30-Day -4.25%

See BSX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Adjusted EPS rose 19% to $0.75, exceeding guidance and signaling robust operational efficiency.
U.S. operations experienced exceptional growth at 27%, while the Asia-Pacific region also performed strongly with a 17% increase.
Although EMEA saw a 2% decline due to temporary headwinds, underlying growth was strong, indicating resilience in key markets.
Full-year adjusted EPS guidance raised to $3.02 to $3.04, reflecting the company's confidence in continued above-market growth.
Upcoming acquisition of Nalu Medical poised to enhance Boston Scientific's portfolio in the interventional pain market, expected to close in H1 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit BSX on AllInvestView.

Next Q1 2026